The newest FDA-approved PET imaging agent for neuroendocrine tumors — DetectnetTM (copper Cu 64 Dotate injection) — is now included in the National Comprehensive Cancer Network ® (NCCN) Clinical Practice Guidelines in Oncology – Neuroendocrine and Adrenal Tumors, version 1.2021. The announcement was made by RadioMedix Inc. and its commercial partner, Curium, on May 5. Detectnet is a positron emission tomography (PET) agent indicated for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults.

This information follows the recent news that the Centers for Medicare & Medicaid Services (CMS) has simplified the coding for Detectnet. Effective April 1, 2021, all sites of care will use code A9592 to submit for reimbursement for all patients. While Transitional Pass-Through Status remains in effect for Detectnet, C9068 was replaced with A9592 beginning April 1, 2021.

To read more please visit:

https://www.carcinoid.org/2021/05/10/detectnet-copper-cu-64-dotatate-injection-now-included-in-nccn-guidelines-for-neuroendocrine-tumors/

Source: The Carcinoid Cancer Foundation